KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $258.0 million.

  • Acadia Pharmaceuticals' Cash & Equivalents rose 6628.92% to $258.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $258.0 million, marking a year-over-year increase of 6628.92%. This contributed to the annual value of $319.6 million for FY2024, which is 6940.21% up from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Cash & Equivalents of $258.0 million as of Q3 2025, which was up 6628.92% from $253.6 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' Cash & Equivalents' 5-year high stood at $319.6 million during Q4 2024, with a 5-year trough of $94.6 million in Q3 2021.
  • Over the past 5 years, Acadia Pharmaceuticals' median Cash & Equivalents value was $188.7 million (recorded in 2023), while the average stood at $194.7 million.
  • Examining YoY changes over the last 5 years, Acadia Pharmaceuticals' Cash & Equivalents showed a top increase of 7594.4% in 2021 and a maximum decrease of 7907.82% in 2021.
  • Acadia Pharmaceuticals' Cash & Equivalents (Quarter) stood at $147.4 million in 2021, then decreased by 22.1% to $114.8 million in 2022, then skyrocketed by 64.27% to $188.7 million in 2023, then skyrocketed by 69.4% to $319.6 million in 2024, then decreased by 19.27% to $258.0 million in 2025.
  • Its Cash & Equivalents stands at $258.0 million for Q3 2025, versus $253.6 million for Q2 2025 and $217.7 million for Q1 2025.